May 28, 2019 — Corindus Vascular Robotics Inc. announced its CorPath GRX System was successfully used to perform a live complex robotic-assisted percutaneous coronary intervention (PCI) at the EuroPCR 2019 Conference, May 21-24 in Paris, France.
Jean Fajadet, M.D., Interventional cardiologist, PCR vice-chairman and course director of EuroPCR, performed the procedure from Clinique Pasteur in Toulouse, France. It was broadcast live to EuroPCR attendees, marking the first time a robotic procedure using CorPath GRX was performed and broadcast live in Europe. Fajadet is the co-director of the interventional cardiology unit at Clinique Pasteur, which became the first site in Europe to adopt Corindus’ most advanced vascular robotic technology when it installed the CorPath GRX System this year.
The CorPath System is the world’s only U.S. Food and Drug Administration (FDA)-cleared and CE marked robotic platform for percutaneous coronary intervention (PCI) and peripheral vascular intervention (PVI) procedures, according to the company. CorPath GRX received CE mark for neurovascular intervention in April 2019, broadening the application of the CorPath GRX System to treat all vascular beds in Europe.
“CorPath GRX offers the level of precision and control necessary to perform even the most complex PCI procedures,” said Fajadet. “The live case went exactly as planned. I was able to complete the procedure with control of all interventional devices and imaging equipment from the control room, providing my patient with high-quality care while protecting myself and the cath lab team. I am pleased to share this technology with my peers to demonstrate how far it has come, and the promising future it may provide patients.”
For more information: www.corindus.com
November 14, 2025 
